Dyslipidemia genetic profile (for research purpose) at Chughtai Lab

Dyslipidemia genetic profile (for research purpose) at Chughtai Lab

Dyslipidemia represents a heterogeneous group of disorders characterized by abnormal levels of lipids—including cholesterol, triglycerides, and lipoproteins—in the blood. While lifestyle factors play a significant role, genetic variations are major determinants of lipid metabolism and cardiovascular risk. The Dyslipidemia genetic profile (for research purpose) at Chughtai Lab is a highly specialized molecular assay designed to identify genetic variants, mutations, and single nucleotide polymorphisms (SNPs) across key genes regulating lipid pathways. This profile is specifically tailored for clinical research, epidemiological studies, and translational medicine, providing researchers and clinicians with deep genomic insights into hereditary lipid disorders.

Lipid homeostasis is tightly regulated by a network of proteins, receptors, and enzymes. Genetic alterations in these components can lead to severe primary dyslipidemias, such as Familial Hypercholesterolemia (FH), Familial Chylomicronemia Syndrome (FCS), and familial combined hyperlipidemia. By utilizing advanced molecular diagnostics, this research-grade genetic profile evaluates the genomic landscape of individuals to map out hereditary predispositions. Understanding these genetic markers is crucial for identifying high-risk cohorts, understanding the pathophysiology of premature atherosclerosis, and developing targeted, personalized therapeutic strategies.

Chughtai Lab, Pakistan’s premier diagnostic network, offers this advanced molecular profiling using state-of-the-art genomic technologies. The assay targets critical genes including LDLR, APOB, PCSK9, LPL, and APOE, among others. By analyzing these loci, researchers can correlate genotype with phenotype, stratify cardiovascular risk with greater precision, and contribute to the global database of genetic variations associated with lipid metabolism. This comprehensive approach ensures that academic and clinical research projects are backed by highly accurate, reproducible, and clinically relevant genomic data.

Clinical Procedure: What to Expect

Patient Preparation

Unlike routine biochemical lipid profiles that measure serum cholesterol and triglyceride levels, the Dyslipidemia genetic profile (for research purpose) analyzes genomic DNA. Therefore, patient preparation differs significantly from standard blood tests:

• No Fasting Required: Because genomic DNA remains constant regardless of dietary intake, fasting is not mandatory for this test. Patients may eat and drink normally prior to sample collection.
• Medication Status: Standard lipid-lowering medications, such as statins, fibrates, or PCSK9 inhibitors, do not alter genomic DNA and do not need to be discontinued. However, patients should inform the laboratory of all ongoing therapies for documentation.
• Blood Transfusion History: Patients who have received a recent blood transfusion (within the last 3 to 4 months) should notify the clinical staff, as donor DNA can interfere with the accuracy of the genetic analysis.
• Hydration: Adequate hydration is recommended prior to venipuncture to ensure easy venous access and a smooth sample collection process.
• Informed Consent: Since this is a genetic test conducted for research purposes, patients or research participants must sign an informed consent form detailing the scope, utility, and privacy protocols of the genetic analysis.

During the Procedure

The sample collection and laboratory processing for the Dyslipidemia genetic profile (for research purpose) follow strict molecular biology protocols to prevent contamination and ensure DNA integrity:

• Venipuncture: A certified phlebotomist at Chughtai Lab will identify a suitable vein, typically in the antecubital fossa of the arm. The area is thoroughly sanitized with an antiseptic swab.
• Sample Collection: Approximately 3 to 5 mL of whole blood is drawn into an EDTA (ethylenediaminetetraacetic acid) tube, easily identified by its lavender or purple top. EDTA is the preferred anticoagulant as it preserves cellular morphology and prevents DNA degradation.
• Labeling and Transport: The sample is immediately labeled with unique barcoded identifiers to maintain patient anonymity and traceability. It is transported to the molecular diagnostics division under controlled temperature conditions (typically 2°C to 8°C).
• DNA Extraction: In the laboratory, molecular specialists perform genomic DNA extraction using automated platforms. The extracted DNA is quantified and assessed for purity using spectrophotometric methods.
• Genomic Analysis: The DNA undergoes amplification and sequencing using advanced platforms, such as Next-Generation Sequencing (NGS) or multiplex polymerase chain reaction (PCR), depending on the specific research panel requirements.
• Safety and Comfort: The venipuncture process is quick, lasting less than five minutes, and involves minimal discomfort. Standard sterile precautions are strictly maintained to eliminate any risk of infection.

When is a Dyslipidemia genetic profile (for research purpose) Performed?

Investigating Familial Hypercholesterolemia (FH) Cohorts

Familial Hypercholesterolemia is a severely underdiagnosed autosomal dominant disorder characterized by lifelong elevations of low-density lipoprotein cholesterol (LDL-C) and a high risk of premature coronary artery disease. Researchers utilize the Dyslipidemia genetic profile (for research purpose) to identify pathogenic variants in the LDLR, APOB, and PCSK9 genes within specific cohorts. This assists in mapping the prevalence of FH mutations in the population, enabling cascade screening of family members and facilitating early clinical intervention studies.

Stratifying Cardiovascular Risk in Clinical Research

Traditional risk calculators often fail to capture the full spectrum of cardiovascular risk in individuals with atypical clinical presentations. In clinical trials and longitudinal studies, researchers employ this genetic profile to identify subclinical genetic risks. By analyzing specific genetic variants associated with accelerated atherosclerosis, researchers can better stratify study participants, leading to more robust clinical trial designs and a deeper understanding of the genetic drivers of cardiovascular events.

Evaluating Polygenic Risk Scores for Lipid Disorders

While monogenic lipid disorders are caused by single high-impact mutations, many individuals exhibit dyslipidemia due to the cumulative effect of multiple low-impact genetic variants. This genetic profile allows researchers to calculate polygenic risk scores (PRS) by analyzing a broad spectrum of single nucleotide polymorphisms (SNPs). This research helps determine how polygenic inheritance interacts with environmental factors to influence overall lipid levels and cardiovascular outcomes.

Pharmacogenomic Studies and Drug Response Research

Response to lipid-lowering therapies, such as statins, varies widely among individuals due to genetic differences. Researchers use this profile to study pharmacogenomic markers, such as variations in the SLCO1B1 gene, which are linked to statin-induced myopathy, or variants in the CETP and PCSK9 genes that influence drug efficacy. This research is pivotal for developing personalized medicine protocols that optimize therapeutic efficacy while minimizing adverse drug reactions.

Academic and Epidemiological Population Studies

Epidemiological research aims to understand the genetic architecture of diverse populations. In Pakistan, where consanguineous marriages are common, the genetic landscape of lipid disorders may exhibit unique mutational spectrums. The Dyslipidemia genetic profile (for research purpose) provides academic researchers with the high-resolution genomic data necessary to identify novel population-specific variants, contributing valuable data to global genomic databases and public health research.

What Does a Dyslipidemia genetic profile (for research purpose) Detect?

This advanced molecular profile is designed to detect a wide array of genetic variations, mutations, and polymorphisms. Specifically, the assay evaluates and detects:

• LDLR Pathogenic Mutations: Detects single nucleotide variants, insertions, or deletions in the Low-Density Lipoprotein Receptor gene, which are primary causes of familial hypercholesterolemia.
• APOB Ligand-Binding Variants: Identifies mutations in the Apolipoprotein B gene that impair the binding of LDL particles to their receptors, leading to hypercholesterolemia.
• PCSK9 Gain-of-Function Mutations: Detects genetic variants that increase PCSK9 activity, leading to rapid degradation of LDL receptors and elevated circulating LDL levels.
• LDLRAP1 Recessive Mutations: Identifies mutations in the LDLR adaptor protein 1 gene, responsible for autosomal recessive hypercholesterolemia.
• LPL Loss-of-Function Variants: Detects mutations in the Lipoprotein Lipase gene, which lead to severe hypertriglyceridemia and chylomicronemia syndrome.
• APOC2 Gene Mutations: Identifies deficiencies in Apolipoprotein C2, an essential cofactor for lipoprotein lipase activation.
• APOE Allelic Variations: Determines the presence of APOE e2, e3, and e4 alleles, which influence cholesterol clearance and susceptibility to cardiovascular disease.
• CETP Polymorphisms: Detects variations in the Cholesteryl Ester Transfer Protein gene, affecting high-density lipoprotein (HDL) metabolism.
• ABCA1 Gene Mutations: Identifies defects in the ATP-Binding Box Transporter A1, associated with Tangier disease and extremely low HDL levels.
• APOA1 Gene Variants: Detects mutations in the Apolipoprotein A1 gene, leading to hereditary hypoalphalipoproteinemia.
• LCAT Gene Defects: Identifies mutations in the Lecithin-Cholesterol Acyltransferase gene, which impair cholesterol esterification.
• ABCG5 and ABCG8 Mutations: Detects genetic variants responsible for sitosterolemia, a rare lipid storage disorder.
• LPA Gene Kringle Repeats: Evaluates genetic variations in the Lipoprotein(a) gene, which correlate with elevated Lp(a) levels and independent cardiovascular risk.
• SAR1B Mutations: Identifies genetic defects linked to chylomicron retention disease.
• ANGPTL3 Loss-of-Function Variants: Detects mutations in the Angiopoietin-like 3 gene, associated with familial combined hypolipidemia.
• APOC3 Promoter Polymorphisms: Identifies variants that influence the expression of Apolipoprotein C3, a regulator of triglyceride-rich lipoprotein clearance.
• LDLR Promoter Region Variants: Detects non-coding mutations that alter the transcriptional regulation of the LDL receptor.
• Polygenic SNP Panels: Evaluates a pre-defined set of single nucleotide polymorphisms used to calculate polygenic risk scores for elevated LDL-C.
• Variants of Uncertain Significance (VUS): Identifies novel or rare genetic changes in lipid-related pathways that require further functional characterization.
• SLCO1B1 Pharmacogenomic Markers: Detects the c.521T>C variant associated with reduced hepatic uptake of statins and increased risk of myopathy.
• Copy Number Variations (CNVs): Identifies large-scale duplications or deletions within the LDLR gene structure.
• GPAM Gene Variants: Evaluates polymorphisms in the glycerol-3-phosphate acyltransferase gene linked to triglyceride synthesis.
• PCSK9 Loss-of-Function Variants: Detects protective mutations that lead to lifelong low LDL-C levels and reduced cardiovascular risk.
• LIPA Gene Mutations: Identifies defects in the Lysosomal Acid Lipase gene, associated with cholesteryl ester storage disease.

Turnaround Time and Report Access at Chughtai Lab

Due to the complex nature of genomic sequencing, DNA extraction, and bioinformatics analysis, the turnaround time for the Dyslipidemia genetic profile (for research purpose) is longer than routine biochemical assays. Typically, comprehensive genetic profiling reports are finalized within 14 to 21 working days. This timeline ensures rigorous quality control, variant annotation, and validation of any detected mutations by our expert molecular pathologists.

Chughtai Lab provides seamless and secure access to research reports. Once the analysis is complete, the primary researcher or patient is notified via SMS. Reports can be securely downloaded through the official Chughtai Lab online portal or the Chughtai Lab mobile application. For large-scale research projects, customized data delivery formats, including raw FASTQ or VCF files, can be arranged through our specialized molecular diagnostics department, ensuring smooth integration into research databases.

Dyslipidemia genetic profile (for research purpose) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
LDLR Gene	Wild-type sequence; normal LDL receptor expression and function.	Pathogenic mutations (missense, nonsense, CNVs) leading to Familial Hypercholesterolemia.
APOB Gene	Normal apolipoprotein B-100 sequence; optimal binding to LDL receptors.	Mutations in the ligand-binding domain impairing LDL clearance (Familial Defective ApoB).
PCSK9 Gene	Standard PCSK9 activity; balanced regulation of LDL receptor recycling.	Gain-of-function mutations (elevated LDL) or loss-of-function mutations (protective low LDL).
LPL Gene	Fully functional lipoprotein lipase; normal clearance of chylomicrons and VLDL.	Loss-of-function mutations causing severe hypertriglyceridemia or Familial Chylomicronemia.
APOE Genotype	Presence of e3/e3 genotype (associated with average lipid metabolism).	e4/e4 genotype (increased cardiovascular risk) or e2/e2 genotype (type III hyperlipoproteinemia risk).
ABCA1 Gene	Normal cellular cholesterol efflux to lipid-poor apolipoproteins.	Homozygous or heterozygous mutations leading to Tangier disease or severe hypoalphalipoproteinemia.
SLCO1B1 Gene	Normal OATP1B1 transporter function (T/T genotype).	C allele variant (C/C or T/C) associated with decreased statin clearance and high risk of myopathy.
LPA Gene	Standard kringle IV type 2 repeat number associated with low circulating Lp(a).	Low copy number of kringle IV repeats leading to elevated Lipoprotein(a) and high atherogenic risk.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Dyslipidemia genetic profile (for research purpose)?

• Advanced Molecular Diagnostics Division: Chughtai Lab features a highly specialized genomics department equipped with cutting-edge Next-Generation Sequencing (NGS) and PCR technologies.
• College of American Pathologists (CAP) Standards: Our laboratory processes adhere to stringent international quality standards, ensuring maximum accuracy and reproducibility of genetic data.
• Highly Qualified Pathologists: The molecular diagnostics team is led by experienced molecular pathologists and geneticists who provide expert interpretation of complex genomic variants.
• Comprehensive Research Support: We offer tailored solutions for clinical trials, academic research, and epidemiological studies, including customizable gene panels and raw data export.
• Convenient Home Sample Collection: Chughtai Lab provides professional home sampling services across Pakistan, allowing research participants to provide samples from the comfort of their homes.
• Robust Data Privacy and Security: We maintain strict confidentiality protocols to protect sensitive genetic data, ensuring compliance with ethical research standards.
• Nationwide Network: With over 300 collection centers across major cities like Lahore, Karachi, and Islamabad, sample logistics are handled seamlessly with strict cold chain maintenance.
• Digital Access to Reports: Researchers and patients can easily track sample status and download comprehensive reports via the Chughtai Lab mobile app and online portal.